171 related articles for article (PubMed ID: 19803560)
1. Call for comparative effectiveness research: lowering A1c with sitagliptin, saxagliptin, or cinnamon.
Fairman KA; Curtiss FR
J Manag Care Pharm; 2009 Oct; 15(8):696-700. PubMed ID: 19803560
[No Abstract] [Full Text] [Related]
2. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Mikhail N
Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
[TBL] [Abstract][Full Text] [Related]
3. Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis.
Gerrald KR; Van Scoyoc E; Wines RC; Runge T; Jonas DE
Diabetes Obes Metab; 2012 Jun; 14(6):481-92. PubMed ID: 22098472
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
Scheen AJ; Charpentier G; Ostgren CJ; Hellqvist A; Gause-Nilsson I
Diabetes Metab Res Rev; 2010 Oct; 26(7):540-9. PubMed ID: 20824678
[TBL] [Abstract][Full Text] [Related]
5. [Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].
Jermendy G
Orv Hetil; 2011 Sep; 152(37):1471-6. PubMed ID: 21893477
[TBL] [Abstract][Full Text] [Related]
6. DPP-4 inhibitors in clinical practice.
Palalau AI; Tahrani AA; Piya MK; Barnett AH
Postgrad Med; 2009 Nov; 121(6):70-100. PubMed ID: 19940419
[TBL] [Abstract][Full Text] [Related]
7. [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
Gallwitz B
Pharm Unserer Zeit; 2010 Mar; 39(2):114-8. PubMed ID: 20196038
[No Abstract] [Full Text] [Related]
8. Initial therapy for type 2 diabetes. Examination of a combination approach.
Henson K; Hight R; Welborn D; Wyatt S
Adv Nurse Pract; 2009 Jun; 17(6):43-4. PubMed ID: 20000183
[No Abstract] [Full Text] [Related]
9. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Scheen AJ
Diabetes Metab; 2012 Apr; 38(2):89-101. PubMed ID: 22197148
[TBL] [Abstract][Full Text] [Related]
10. Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1).
Lumb AN; Gallen IW
Diabet Med; 2009 Feb; 26(2):189-90. PubMed ID: 19236626
[No Abstract] [Full Text] [Related]
11. Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes.
Poucher SM; Cheetham S; Francis J; Zinker B; Kirby M; Vickers SP
Diabetes Obes Metab; 2012 Oct; 14(10):918-26. PubMed ID: 22564773
[TBL] [Abstract][Full Text] [Related]
12. Managed care perspective on three new agents for type 2 diabetes.
VanDeKoppel S; Choe HM; Sweet BV
J Manag Care Pharm; 2008 May; 14(4):363-80. PubMed ID: 18500914
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.
Fakhoury WK; Lereun C; Wright D
Pharmacology; 2010; 86(1):44-57. PubMed ID: 20616619
[TBL] [Abstract][Full Text] [Related]
14. Sitagliptin (Januvia) for type 2 diabetes.
Med Lett Drugs Ther; 2007 Jan; 49(1251):1-3. PubMed ID: 17179897
[No Abstract] [Full Text] [Related]
15. [Combination antidiabetic therapy. Better control of blood glucose values].
Bischoff A
MMW Fortschr Med; 2009 Oct; 151(42):55. PubMed ID: 19938787
[No Abstract] [Full Text] [Related]
16. DPP4 inhibitors: a new approach in diabetes treatment.
Doupis J; Veves A
Adv Ther; 2008 Jul; 25(7):627-43. PubMed ID: 18641927
[TBL] [Abstract][Full Text] [Related]
17. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.
Ahrén B
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):487-98. PubMed ID: 19748066
[TBL] [Abstract][Full Text] [Related]
18. New treatments for diabetes.
Bloomgarden ZT; Inzucchi SE
N Engl J Med; 2007 May; 356(21):2219-20; author reply 2222-3. PubMed ID: 17522409
[No Abstract] [Full Text] [Related]
19. Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus.
Neumiller JJ; Campbell RK
Am J Health Syst Pharm; 2010 Sep; 67(18):1515-25. PubMed ID: 20811029
[TBL] [Abstract][Full Text] [Related]
20. [Sitagliptin in the treatment of type 2 diabetes: new data presented during the American Diabetes Association annual meeting (San Diego, California, June 2011)].
Rabasseda X
Drugs Today (Barc); 2011 Nov; 47 Suppl D():1-8. PubMed ID: 22439134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
